ArticleProceedings of the National Academy of Sciences of the United States of America2004
A rare-cell detector for cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 340 citations in OpenAlex.
- Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.Archives of medical research · 2015Trial
- Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.Breast cancer research and treatment · 2011Trial
- Advances in microfluidic platforms for tumor cell phenotyping: from bench to bedside.Lab on a chip · 2025Review
- The integrated on-chip isolation and detection of circulating tumour cells.Sensors & diagnostics · 2024Review
- Enhanced particle separation through ultrasonically-induced microbubble streaming for automated size-selective particle depletion.RSC advances · 2024Article
- Liquid-based biomarkers in breast cancer: looking beyond the blood.Journal of translational medicine · 2023Review
- A Micropillar Array Based Microfluidic Device for Rare Cell Detection and Single-Cell Proteomics.Methods and protocols · 2023Article
- Advances in Ultrahigh Throughput Hit Discovery with Tandem Mass Spectrometry Encoded Libraries.Journal of the American Chemical Society · 2023Review
- Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023Review
- Clinical application and detection techniques of liquid biopsy in gastric cancer.Molecular cancer · 2023Review
- Multifunctional Gelatin-Nanoparticle-Modified Chip for Enhanced Capture and Non-Destructive Release of Circulating Tumor Cells.Micromachines · 2022Article
- Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers.ACS central science · 2022Article
- Review
- Comprehensive Atlas of Circulating Rare Cells Detected by SE-iFISH and Image Scanning Platform in Patients With Various Diseases.Frontiers in oncology · 2022Article
- Negative-Selection Enrichment of Circulating Tumor Cells from Peripheral Blood Using the Microfluidic CTC-iChip.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device.Scientific reports · 2021Article
- Circulating tumor cell profiling for precision oncology.Molecular oncology · 2021Review
- Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.Bioconjugate chemistry · 2020Article
- A circulating tumor cell-based digital assay for the detection of EGFR T790M mutation in advanced non-small cell lung cancer.Journal of materials chemistry. B · 2020Article
- A Review on Microdevices for Isolating Circulating Tumor Cells.Micromachines · 2020Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although a reliable method for detection of cancer cells in blood would be an important tool for diagnosis and monitoring of solid tumors in early stages, current technologies cannot reliably detect the extremely low concentrations of these rare cells. The preferred method of detection, automated digital microscopy (ADM), is too slow to scan the large substrate areas. Here we report an approach that uses fiber-optic array scanning technology (FAST), which applies laser-printing techniques to the rare-cell detection problem. With FAST cytometry, laser-printing optics are used to excite 300,000 cells per sec, and emission is collected in an extremely wide field of view, enabling a 500-fold speed-up over ADM with comparable sensitivity and superior specificity. The combination of FAST enrichment and ADM imaging has the performance required for reliable detection of early-stage cancer in blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.